Production (Stage)
ANI Pharmaceuticals, Inc.
ANIP
$57.79
$0.520.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 674.07M | 614.38M | 555.46M | 538.95M | 517.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 674.07M | 614.38M | 555.46M | 538.95M | 517.46M |
| Cost of Revenue | 274.09M | 250.21M | 223.35M | 208.38M | 192.96M |
| Gross Profit | 399.98M | 364.17M | 332.11M | 330.58M | 324.50M |
| SG&A Expenses | 264.84M | 237.24M | 212.18M | 183.91M | 173.25M |
| Depreciation & Amortization | 75.94M | 67.73M | 60.33M | 59.78M | 59.78M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 659.50M | 599.76M | 533.66M | 490.87M | 464.86M |
| Operating Income | 14.57M | 14.62M | 21.80M | 48.09M | 52.60M |
| Income Before Tax | -27.56M | -22.21M | -7.50M | 35.51M | 43.04M |
| Income Tax Expenses | -6.51M | -3.69M | -412.00K | 8.49M | 7.50M |
| Earnings from Continuing Operations | -21.05 | -18.52 | -7.09 | 27.02 | 35.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.05M | -18.52M | -7.09M | 27.02M | 35.55M |
| EBIT | 14.57M | 14.62M | 21.80M | 48.09M | 52.60M |
| EBITDA | 90.50M | 82.35M | 82.13M | 107.87M | 112.38M |
| EPS Basic | -1.16 | -1.02 | -0.44 | 1.29 | 1.63 |
| Normalized Basic EPS | -0.25 | -0.22 | 0.07 | 0.87 | 0.96 |
| EPS Diluted | -1.18 | -1.04 | -0.45 | 1.27 | 1.60 |
| Normalized Diluted EPS | -0.26 | -0.23 | 0.06 | 0.86 | 0.94 |
| Average Basic Shares Outstanding | 77.78M | 77.27M | 76.83M | 76.31M | 74.67M |
| Average Diluted Shares Outstanding | 78.22M | 77.59M | 77.37M | 77.09M | 75.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -7.72% | -8.77% | -22.92% | 6.02% | 4.57% |